Protara Therapeutics Inc
NASDAQ:TARA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
TARA's latest stock split occurred on Jan 10, 2020
The company executed a 1-for-40 stock split, meaning that for every 40 shares held, investors received 1 new share.
Before the split, TARA traded at 0.8352 per share. Afterward, the share price was about 30.
The adjusted shares began trading on Jan 10, 2020. This was the only stock split in TARA's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 22, 2026
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
1-for-100
/100
|
0.002 0.2 AUD | 0.17 0.17 AUD |
|
Apr 22, 2026
|
|
Architects Studio Japan Inc
TSE:6085
|
10-for-1
x10
|
3800 380 JPY | 430 430 JPY |
|
Apr 22, 2026
|
|
Freewon China Co Ltd
SSE:688678
|
1-for-1
x1
|
30.5 21.6857 CNY | 23.64 23.64 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
|
Apr 21, 2026
|
|
Canon Electronics Inc
OTC:CAOEF
|
1-for-6235122
/6235122
|
16.96 16.96 USD | N/A |
CHM
6085
688678
CAOEF
Protara Therapeutics Inc
Glance View
Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 31 full-time employees. The company went IPO on 2014-10-22. The firm is focused on identifying therapies for the treatment of cancer and rare diseases. The firm's pipeline includes TARA-002 and IV Choline Chloride. The firm's lead product pipeline is TARA 002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an investigational, intravenous (IV) phospholipid substrate replacement therapy, which is in development for patients receiving parenteral nutrition (PN) who have intestinal failure-associated liver disease (IFALD).
